Clinuvel Pharmaceuticals Progresses Preclinical Program Studying Drug Release Profiles

MT Newswires Live

Sep 29

Clinuvel Pharmaceuticals (ASX:CUV) said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.

The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.

If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571875573"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571875573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571875573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 08:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571875573","market":"hk","top_or_hot":-1,"title":"Clinuvel Pharmaceuticals Progresses Preclinical Program Studying Drug Release Profiles","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.</p><p>The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.</p><p>If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel Pharmaceuticals Progresses Preclinical Program Studying Drug Release Profiles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel Pharmaceuticals Progresses Preclinical Program Studying Drug Release Profiles\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-29 08:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.</p><p>The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.</p><p>If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CUV.AU","symbol_name":"CLINUVEL PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2571875573","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571875573","pubTimestamp":1759105587,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clinuvel Pharmaceuticals  said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Clinuvel Pharmaceuticals推进研究药物释放曲线的临床前计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUV.AU":1},"content_text":"Clinuvel Pharmaceuticals (ASX:CUV) said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}